<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230104057040N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-08</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Nutrition education with extended parallel model in diabetic patients for improving glycemic indices and lipid profile control and adherence to the proper diet</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating of the effect of educational intervention based on the developed parallel process model on the adherence to the proper diet, glycemic factors, and lipid profile in middle-aged people with type 2 diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>88</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67816</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Factorial, Purpose: Prevention, Randomization description: For data gathering, first, name and address of all health centers of Bowanat city were extracted and from 8 centers, four centers were selected by random multi-stage method. After selecting 4 centers, each center was allocated to a group of intervention or control group by lottery, in order not to let the patients visit each other and not to distort the results. Then, from each center, 22 patients were  selected from eligible middle-aged diabetic patients with simple random sampling, Blinding description: the study was single blind. Data analyzer was not also informed of groupings.At the time of analysis, the analyzer was informed that 4 groups with the names of A,B,C,D were available and he/she was not informed of group characteristics.</study_design>
      <phase>3</phase>
      <hc_freetext>Type 2 Diabetes.</hc_freetext>
      <i_freetext>Intervention 1: 1- Control group:routine educations for 3 months (82 messages in the form of images and clips, almost 5 messages per day via virtual media such as messengers and by formation of virtual groups). Intervention 2: 1- Intervention group: gain-frame messages group for 3 months (82 messages in the form of images and clips, almost 5 messages per day via virtual media such as messengers and by formation of virtual groups ). Intervention 3: 2- Intervention group:loss-frame messages group for 3 months(78 messages in the form of images and clips, almost 5 messages per day via virtual media such as messengers and by formation of virtual groups). Intervention 4: 3- Intervention group: combined messages group for 3 months (157 messages in the form of images and clips, almost 5 messages per day via virtual media such as messengers and by formation of virtual groups).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The final results will be shared.

When:
After publishing the article.

To whom:
Now it is available for the analyzer and the main investigators.

Conditions:
Only with permission from the investigator

Where to obtain:
By contacting the investigator

How to obtain:
By asking from e-mail (email address: Sohrabi@sums.ac.ir)

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Tayebe Dehghan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi avenue</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۳۳۶۷۱۳۴۸</zip>
        <telephone>+98 917 566 2643</telephone>
        <email>dehghant89@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Sohrabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi avenue</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۳۳۶۷۱۳۴۸</zip>
        <telephone>+98 917 711 3086</telephone>
        <email>Zahra_2043@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age range: 30-59 years old (middle age)
Having type 2 diabetes and not using insulin (FBS higher than 125 and 2-hr glucose higher than 200 mg/dl)
Not having chronic diseases including cancer, kidney or liver diseases
Not using special drugs, not smoking
Having no special diet
Not being pregnant or lactating</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>59 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Incidence of any chronic or acute diseases or incidence of some diseases such as kidney diseases
Sudden disturbances of blood glucose including sudden and dangerous hypo- or hyperglycemia
Acute or respiratory infections
Any surgery
Following any special diet or physical activity regiment</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>1- Control group:routine educations for 3 months (82 messages in the form of images and clips, almost 5 messages per day via virtual media such as messengers and by formation of virtual groups)</i_keyword>
      <i_keyword>1- Intervention group: gain-frame messages group for 3 months (82 messages in the form of images and clips, almost 5 messages per day via virtual media such as messengers and by formation of virtual groups )</i_keyword>
      <i_keyword>2- Intervention group:loss-frame messages group for 3 months(78 messages in the form of images and clips, almost 5 messages per day via virtual media such as messengers and by formation of virtual groups)</i_keyword>
      <i_keyword>3- Intervention group: combined messages group for 3 months (157 messages in the form of images and clips, almost 5 messages per day via virtual media such as messengers and by formation of virtual groups)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Glycosylated hemoglobin. Timepoint: At baseline and after 3 months. Method of measurement: High performance liquid chromatography (HPLC).</prim_outcome>
      <prim_outcome>Fasting blood glucose. Timepoint: At baseline and after 3 months. Method of measurement: Calorimetric method by using auto-analyzer.</prim_outcome>
      <prim_outcome>2 hour- blood glucose. Timepoint: At baseline and after 3 months. Method of measurement: Calorimetric method by using auto-analyzer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Low density lipoprotein-cholestrol. Timepoint: At baseline and after 3 months. Method of measurement: Calorimetric method by using auto-analyzer.</sec_outcome>
      <sec_outcome>High density lipoprotein-cholestrol. Timepoint: At baseline and after 3 months. Method of measurement: Calorimetric method by using auto-analyzer.</sec_outcome>
      <sec_outcome>Total cholestrol. Timepoint: At baseline and after 3 months. Method of measurement: Calorimetric method by using auto-analyzer.</sec_outcome>
      <sec_outcome>Triglyceride. Timepoint: At baseline and after 3 months. Method of measurement: Calorimetric method by using auto-analyzer.</sec_outcome>
      <sec_outcome>Weight. Timepoint: At baseline and after 3 months. Method of measurement: With scale.</sec_outcome>
      <sec_outcome>Height. Timepoint: At baseline and after 3 months. Method of measurement: With tape meter.</sec_outcome>
      <sec_outcome>Body mass index. Timepoint: At baseline and after 3 months. Method of measurement: With calculation from weight and height.</sec_outcome>
      <sec_outcome>Waist circumference. Timepoint: At baseline and after 3 months. Method of measurement: With tape meter.</sec_outcome>
      <sec_outcome>Hip circumference. Timepoint: At baseline and after 3 months. Method of measurement: With tape meter.</sec_outcome>
      <sec_outcome>Waist to hip ratio. Timepoint: At baseline and after 3 months. Method of measurement: Calculate form waist and hip measurements.</sec_outcome>
      <sec_outcome>Physical activity. Timepoint: At baseline and after 3 months. Method of measurement: With questionnaire.</sec_outcome>
      <sec_outcome>Knowledge level. Timepoint: At baseline and after 3 months. Method of measurement: With questionnaire.</sec_outcome>
      <sec_outcome>Perceived sensitivity. Timepoint: At baseline and after 3 months. Method of measurement: With questionnaire.</sec_outcome>
      <sec_outcome>Perceived severity. Timepoint: At baseline and after 3 months. Method of measurement: With questionnaire.</sec_outcome>
      <sec_outcome>Perceived effectiveness. Timepoint: At baseline and after 3 months. Method of measurement: With questionnaire.</sec_outcome>
      <sec_outcome>Self-efficacy. Timepoint: At baseline and after 3 months. Method of measurement: With questionnaire.</sec_outcome>
      <sec_outcome>Intention. Timepoint: At baseline and after 3 months. Method of measurement: With questionnaire.</sec_outcome>
      <sec_outcome>Food intake of macro nutrients and calorie. Timepoint: 3-day dietary recall. Method of measurement: With questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-07-18</approval_date>
        <contact_name>Shiraz University of Medical Sciences</contact_name>
        <contact_address>Razi Avenue Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
